Trans-pralsetinib
CAS : 2097132-93-7
Ref. 3D-XID13293
| 1mg | Arrêté | ||
| 5mg | Arrêté | ||
| 10mg | Arrêté | ||
| 25mg | Arrêté | ||
| 50mg | Arrêté | ||
| 100mg | Arrêté |
Informations sur le produit
Trans-pralsetinib is a macrocyclic compound with a platinum-based chemotherapy. It is an inhibitor of cyclin-dependent kinases CDK4 and CDK6 and inhibits the phosphorylation of these proteins, which prevents cell cycle progression. Trans-pralsetinib has been shown to be effective in treating solid tumours such as lung cancer and pancreatic cancer. The drug has also been observed to have pharmacokinetic properties that are similar to those of sorafenib, another drug used for cancer treatment. Trans-pralsetinib can be detected in biological samples at levels equivalent to those found in plasma after oral administration of 10mg/kg doses. This drug was well tolerated in Phase I clinical trials, with the most common side effects being gastrointestinal disorders (nausea, vomiting) and skin lesions.
